{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:54:14Z","timestamp":1783698854132,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.072","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:25:08Z","timestamp":1645889108000},"page":"2168-2172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions"],"prefix":"10.1016","volume":"40","author":[{"given":"Wiebke","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammo","family":"Reinders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Schink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.vaccine.2022.02.072_b0005","first-page":"205","article-title":"Measles vaccines: WHO position paper","volume":"92","author":"World Health Organization (WHO)","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"15","key":"10.1016\/j.vaccine.2022.02.072_b0010","first-page":"145","article-title":"Progress towards measles elimination, western hemisphere, 2002\u20132003","volume":"79","author":"World Health Organization (WHO)","year":"2004","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.072_b0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/bmb\/lds019","article-title":"Varicella vaccines","volume":"103","author":"Flatt","year":"2012","journal-title":"Br Med Bull"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.072_b0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s15010-007-6337-z","article-title":"Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age","volume":"35","author":"Goh","year":"2007","journal-title":"Infection"},{"issue":"47","key":"10.1016\/j.vaccine.2022.02.072_b0025","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"issue":"34","key":"10.1016\/j.vaccine.2022.02.072_b0030","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1016\/j.vaccine.2009.05.056","article-title":"Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting","volume":"27","author":"Jacobsen","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.072_b0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.072_b0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.vaccine.2013.12.011","article-title":"Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination","volume":"32","author":"Schink","year":"2014","journal-title":"Vaccine"},{"issue":"RR-3","key":"10.1016\/j.vaccine.2022.02.072_b0045","article-title":"Use of combination measles, mumps, rubella, and varicella vaccine - recommendations of the advisory committee on immunization practices","volume":"59","author":"Marin","year":"2010","journal-title":"MMRW Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.02.072_b0050","first-page":"352","article-title":"Zur Kombinationsimpfung gegen Masern, Mumps, R\u00f6teln und Varizellen (MMRV)","volume":"38","author":"St\u00e4ndige Impfkommission (STIKO)","year":"2011","journal-title":"Epidemiologisches Bullet"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.072_b0055","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2014.10.071","article-title":"Febrile seizures following measles and varicella vaccines in young children in Australia","volume":"33","author":"Macartney","year":"2015","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.072_b0060","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.vaccine.2009.02.044","article-title":"Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age","volume":"27","author":"Halperin","year":"2009","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2022.02.072_b0065","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1016\/j.vaccine.2014.08.067","article-title":"Analysis of safety data in children after receiving two doses of ProQuad(R) (MMRV)","volume":"32","author":"Klopfer","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.072_b0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamapediatrics.2017.1965","article-title":"Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia","volume":"171","author":"Macartney","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.072_b0075","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.vaccine.2012.02.062","article-title":"Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad\u00ae) in infants from 9 months of age","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.072_b0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.1545","article-title":"Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations","volume":"17","author":"Pigeot","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.072_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-015-1943-7","article-title":"Mortality in the German Pharmacoepidemiological Research Database (GePaRD) compared to national data in Germany: results from a validation study","volume":"15","author":"Ohlmeier","year":"2015","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.072_b0090","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/pds.4005","article-title":"Validating mortality in the German Pharmacoepidemiological Research Database (GePaRD) against a mortality registry","volume":"25","author":"Ohlmeier","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.072_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12874-017-0407-4","article-title":"The impact of the lookback period and definition of confirmatory events on the identification of incident cancer cases in administrative data","volume":"17","author":"Czwikla","year":"2017","journal-title":"BMC Med Res Method"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.072_b0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00787-013-0395-9","article-title":"Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study","volume":"22","author":"D\u00f6rks","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.072_b0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00228-014-1697-7","article-title":"Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital","volume":"70","author":"Jobski","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.072_b0110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40264-017-0511-8","article-title":"The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study","volume":"40","author":"Jobski","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2022.02.072_b0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CLEP.S173667","article-title":"Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents","volume":"11","author":"Pisa","year":"2019","journal-title":"Clin Epidemiol."},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.072_b0120","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40264-019-00837-y","article-title":"Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study","volume":"42","author":"Sch\u00e4fer","year":"2019","journal-title":"Drug Saf"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2022.02.072_b0125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000369344","article-title":"Estimation of background incidence rates of Guillain-Barre syndrome in Germany - a retrospective cohort study with electronic healthcare data","volume":"43","author":"Hense","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2022.02.072_b0130","first-page":"279","article-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut\/Stand: Juli 2010","volume":"30","author":"St\u00e4ndige Impfkommission (STIKO)","year":"2010","journal-title":"Epidemiologisches Bullet"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.072_b0135","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.vaccine.2008.10.064","article-title":"Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2\u20136 years primed with measles-mumps-rubella (MMR) vaccine","volume":"27","author":"Gillet","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.072_b0140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1542\/peds.2011-3198","article-title":"Measles-containing vaccines and febrile seizures in children age 4 to 6 years","volume":"129","author":"Klein","year":"2012","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.072_b0145","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/INF.0b013e318267fd8b","article-title":"Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin","volume":"31","author":"R\u00fcger","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.072_b0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.inf.0000250689.09396.21","article-title":"Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years","volume":"26","author":"Vesikari","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.02.072_b0155","unstructured":"GlaxoSmithKline Biologicals. Summary of product characteristics proorix-tetra 2017. [Available from: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_MT\/PDF\/Homepage\/Products\/productlisting\/priorix-tetra\/Priorix_Tetra_PI_II_078_18_Apr_2017.pdf]."},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.072_b0160","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.vaccine.2013.12.065","article-title":"Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella","volume":"32","author":"Streng","year":"2014","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2022.02.072_b0165","first-page":"241","article-title":"Varicella vaccines: WHO position paper","volume":"73","author":"World Health Organization (WHO)","year":"1998","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:01Z","timestamp":1759403461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":33,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22002225"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}